People’s Daily Online, Shanghai, June 10th (Han Qing) This morning, the 2022 Fengxian District Biomedical Conference was held in Fengxian New City·Jinhai Lake. The Berger colloidal gold method R&D and production platform construction project, Fengxian nucleic acid biomedical industrial park project, etc. 6 The project focuses on “cloud signing”, with a total investment of 2.7 billion yuan and an estimated output value of 6.65 billion yuan.
The “Cloud Signing” project, covering industrial segments such as traditional Chinese medicine, nucleic acid drugs, vaccines and medical devices, will help Fengxian expand and strengthen the biopharmaceutical industry ecosystem, and effectively promote Fengxian to become the innovative development of traditional Chinese medicine and biopharmaceutical industries. Highland has become the core carrying area of Shanghai’s life and health industry and a gathering place for the biomedical industry.
Li Zheng, Secretary of the District Party Committee of Fengxian District, Shanghai, said that Fengxian’s biomedical conference is sending out invitations to global biopharmaceutical companies for beauty and health. It is the right time to invest in Fengxian. Fengxian will also continue to give full play to its transportation advantages, ecological advantages and regional advantages, seize the construction opportunities of the “Five New Cities” and Lingang New Area, and provide vast space, perfect functions and considerate services. Enterprises are welcome to develop and invest in Fengxian. Societe Generale, meet with beauty, accompany with health, and go to the future together.
At the scene, Mei Jianping, Member of the Party Committee and Vice President of the Shanghai Branch of the Export-Import Bank of China, Guo Min, Chairman of Kangma (Shanghai) Biotechnology Co., Ltd., and Zhao Baihui, General Manager of Shanghai Bojie Medical Technology Co., Ltd. Industry leaders also act as pro-business ambassadors in Fengxian District, actively “endorsement” and “recommendation” for Fengxian, accelerating the gathering of more high-quality enterprises, high-end projects, outstanding talents and entrepreneurial teams to invest in Fengxian. At the same time, Fengxian District also innovated investment promotion methods, broadened investment channels, and launched a global investment partnership program, aiming to select partners in the biomedical industry from around the world and move forward together.
In recent years, Fengxian has focused on launching the “Oriental Beauty Valley” brand, focusing on leading fields such as pharmaceuticals, cosmetics, and food, grasping the initiative, seizing new tracks, and laying out the industrial chain, gathering more than 200 biopharmaceutical companies and introducing Pasteur A number of national-level functional platforms such as the Institute have formed a first-mover advantage in sub-fields such as biological vaccines, modern traditional Chinese medicine, and innovative drugs. In other aspects, it has achieved a number of “Shanghai No. 1” and “National No. 1”.
As an important bearing area of Shanghai’s advanced manufacturing industry, Fengxian has a solid biopharmaceutical industry foundation and a good brand development environment. It is one of the few areas in Shanghai that can realize the production of all types of drugs.
At present, Fengxian has basically formed four functional areas: the core R&D area of Oriental Beauty Valley, the Lingang Fengxian Pilot Demonstration Area, the Fengcheng Innovation and Development Area, and the Hangzhou Bay Transformation and Bearing Area. Chemical raw materials represented by DSM and Abbott have been initially formed. Pharmaceutical and preparation enterprise cluster; biological product enterprise cluster represented by WuXi and RAAS; traditional Chinese medicine enterprise cluster represented by Hutchison and Kaibao; diagnostic reagent and medical device enterprise represented by Berger, Rui Ang and Long Island cluster. There are more than 200 biopharmaceutical enterprises of various types in the region, including 76 above-scale enterprises. In 2021, the industrial output value of above-scale enterprises will reach 22.92 billion yuan. “Oriental Beauty Valley” and “Lingang New Area Life Blue Bay” have also become characteristic parks of Shanghai’s biopharmaceutical industry.